DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Lai CL, Lim SG, Brown NA, et al. A dose-finding study of
once-daily oral telbivudine in HBeAg-positive patients with
chronic hepatitis B virus infection. Hepatology, 2004,
40:719–726.
Lau D, Everhart J, Kleiner D, et al. Long-term follow-up of
patients with chronic hepatitis B treated with interferon alfa.
Gastroenterology, 1997, 113:1660–1667.
Liaw Y, Sung J, Chow W, et al. Lamivudine for patients with
chronic hepatitis B and advanced liver disease. N Engl J Med,
2004, 351:1521–1531.
Limaye A, Corey L, Koelle D, et al. Emergence of ganciclovirresistant
cytomegalovirus disease among recipients of solidorgan
transplants. Lancet, 2000, 356:645–649.
Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus
infections after allogeneic hematopoietic stem cell transplantation:
A survey by the Infectious Diseases Working Party of
the European Group for Blood and Marrow Transplantation.
Bone Marrow Transplant, 2003, 31:481–486.
Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1
plus corticosteroids in severe acute respiratory syndrome:
A preliminary study. JAMA, 2003, 290:3222–3228.
Lowance D, Neumayer H, Legendre CM, et al. Valacyclovir for
the prevention of cytomegalovirus disease after renal transplantation.
N Engl J Med, 1999, 340:1462–1470.
Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the
treatment of hepatitis B e antigen–positive chronic hepatitis
B. N Engl J Med, 2003, 348:808–816.
Marcellin P, Lau GK, Bonino F. Peginterferon alfa-2a alone,
lamivudine alone, and the two in combination in patients with
HBeAg-negative chronic hepatitis B. N Engl J Med, 2004,
351:1206–1217.
Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of
oral ribavirin in the treatment of Crimean-Congo hemorrhagic
fever in Iran. Clin Infect Dis, 2003, 36:1613–1618.
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with
peginterferon and ribavirin for chronic HCV genotype 1 infection.
N Engl J Med, 2009, 360:1827–1838.
McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon
alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C
infection. N Engl J Med, 2009, 361:580–593.
McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir—effects
on HIV-1 replication and resistance. N Engl J
Med, 2007, 356:2614–2621.
Moscona A. Global transmission of oseltamivir-resistant
influenza. N Engl J Med, 2009, 360:953–956.
Noble S, Faulds D. Ganciclovir: An update of its use in the prevention
of cytomegalovirus infection and disease in transplant
recipients. Drugs, 1998, 56:115–146.
Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M
mutation cooperates with nucleotide binding-site mutations,
increasing hepatitis B virus replication and drug resistance. J
Clin Invest, 2001, 107:449–455.
Peters MG, Hann H, Martin P, et al. Adefovir dipivoxil alone or
in combination with lamivudine in patients with lamivudineresistant
chronic hepatitis B. Gastroenterology, 2004, 126:
91–101.
Poynard T, McHutchison J, Manns M, et al. Impact of pegylated
interferon alfa-2b and ribavirin on liver fibrosis in
patients with chronic hepatitis C. Gastroenterology, 2002,
122:1303–1313.
Prusoff WH. Idoxuridine or how it all began. In: Clinical Use of
Antiviral Drugs. (DeClercq, E, ed.), Martinus Nijhoff, Boston,
1988, pp. 15–24.
Raborn GW, Martel AY, Lassonde M, et al. Effective treatment
of herpes simplex labialis with penciclovir cream: Combined
results of two trials. J Am Dent Assoc, 2002, 133:303–309.
Ratanajamit C, Vinther S, Jepsen P, et al. Adverse pregnancy outcome
in women exposed to acyclovir during pregnancy: A
population-based observational study. Scand J Infect Dis,
2003, 35:255–259.
Reddy KR, Nelson DR, Zeuzem S. Ribavirin: Current role in the
optimal clinical management of chronic hepatitis C. J Hepatol,
2009, 50:402–411.
Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial
of foscarnet versus ganciclovir for preemptive therapy of
cytomegalovirus infection after allogeneic stem cell transplantation.
Blood, 2002, 99:1159–1164.
Sacks SL, Wilson B. Famciclovir/penciclovir. Adv Exp Med Biol,
1999, 458:135–147.
Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev,
2001, 14:778–809.
Schirmer P, Holodniy M. Oseltamivir for treatment and prophylaxis
of influenza infection. Expert Opin Drug Saf, 2009,
8:357–371.
Schmidt AC. Antiviral therapy for influenza: A clinical and economic
comparative review. Drugs, 2004, 64:2031–2046.
Schreiber A, Härter G, Schubert A, et al. Antiviral treatment of
cytomegalovirus infection and resistant strains. Expert Opin
Pharmacother, 2009, 10:191–209.
Scott LJ, Keating GM. Entecavir: A review of its use in chronic
hepatitis B. Drugs, 2009, 69:1003–1033.
Seeff LB, Hoofnagle JH. National Institutes of Health Consensus
Development Conference statement: Management of hepatitis
C. Hepatology, 2002, 36(5 suppl 1):S1–S2.
Skinner RB Jr. Imiquimod. Dermatol Clin, 2003, 21:291–300.
Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa
therapy for chronic hepatitis B in children: A multinational
randomized, controlled trial. Gastroenterology, 1998, 114:
988–995.
Sokal EM, Roberts EA, Mieli-Vergani G, et al. Dose ranging
study of the pharmacokinetics, safety, and preliminary efficacy
of lamivudine in children and adolescents with chronic
hepatitis B. Antimicrob Agents Chemother, 2000, 44:
590–597.
Spruance SL, Nett R, Marbury T, et al. Acyclovir cream for treatment
of herpes simplex labialis: Results of two randomized,
doubleblind, vehicle-controlled, multicenter clinical trials.
Antimicrob Agents Chemother, 2002, 46:2238–2243.
Steer CB, Szer J, Sasadeusz J, et al. Varicella-zoster infection
after allogeneic bone marrow transplantation: Incidence, risk
factors and prevention with low-dose aciclovir and ganciclovir.
Bone Marrow Transplant, 2000, 25:657–664.
Steingrimsdottir H, Gruber A, Palm C, et al. Bioavailability of
aciclovir after oral administration of acyclovir and its prodrug
valaciclovir to patients with leukopenia after chemotherapy.
Antimicrob Agents Chemother, 2000, 44:207–209.
Studies of Ocular Complications of AIDS (SOCA) Research
Group, in Collaboration with the AIDS Clinical Trials
Group. Mortality in patients with the acquired immunodeficiency
syndrome treated with either foscarnet or ganciclovir
1621
CHAPTER 58
ANTIVIRAL AGENTS (NONRETROVIRAL)